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Objective: The c-Jun N-terminal kinase (JNK) family regulates fundamental physiological processes
including apoptosis and metabolism. Although JNK2 is known to promote foam cell formation during
atherosclerosis, the potential role of JNK1 is uncertain. We examined the potential inﬂuence of JNK1 and
its negative regulator, MAP kinase phosphatase-1 (MKP-1), on endothelial cell (EC) injury and early
lesion formation using hypercholesterolemic LDLR/ mice.
Methods and results: To assess the function of JNK1 in early atherogenesis, we measured EC apoptosis
and lesion formation in LDLR/ or LDLR//JNK1/ mice exposed to a high fat diet for 6 weeks. En face
staining using antibodies that recognise active, cleaved caspase-3 (apoptosis) or using Sudan IV (lipid
deposition) revealed that genetic deletion of JNK1 reduced EC apoptosis and lesion formation in hy-
percholesterolemic mice. By contrast, although EC apoptosis was enhanced in LDLR//MKP-1/ mice
compared to LDLR/ mice, lesion formation was unaltered.
Conclusion: We conclude that JNK1 is required for EC apoptosis and lipid deposition during early
atherogenesis. Thus pharmacological inhibitors of JNK may reduce atherosclerosis by preventing EC
injury as well as by inﬂuencing foam cell formation.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The JNK family comprises three genes. JNK1 and JNK2 are both
ubiquitously expressed, whereas JNK3 expression is limited to the
brain [1]. Despite overlapping expression patterns, JNK1 and JNK2
target distinct intracellular proteins for phosphorylation and have
speciﬁc functions [2]. JNK family members play important roles in
cardiovascular injury and disease. Animal studies have revealed
that JNK can be activated in arteries in response to injury [3e5] and
during the development of aneurysms [6] or lesions [7,8]. Moreover,
gene transfer of a dominant negative form of JNK reduced neo-
intimal formation in injured arteries [3]. A previous study demon-
strated that JNK2 promotes atherosclerosis by enhancing lipid
uptake by macrophages and subsequent foam cell formation [9].
We recently demonstrated that JNK1 induces the expression
of pro-apoptotic genes at a disease-prone region of the arterial
tree [10]. By contrast, EC at atheroprotected sites expressed MAP
kinase phosphatase-1 (MKP-1), a nuclear-localised dual speciﬁcityans).
Ireland Ltd. This is an open accessphosphatase that inactivates JNK (and its sister molecule p38) by
dephosphorylating threonine and tyrosine residues in the activa-
tion loop [10e12]. Despite these insights, the potential role of JNK1
in atherosclerosis remains uncertain. Here we tested the novel
hypothesis that a balance between MKP-1 and JNK1 activities
regulates EC apoptosis and lesion formation in early atherogenesis.
2. Materials and methods
2.1. Crossing and maintenance of animals
LDLR/ mice on a C57BL/6 genetic background were obtained
commercially from Jackson laboratories and then bred in-house
[13]. JNK1/ mice were generated by Professor Flavell [14] and
obtained from Professor Roger Davis from the University of Mas-
sachusetts, USA. JNK1-deﬁcient mice were crossed with LDLR/
mice to produce the LDLR//JNK1/ strain (Supplemental Fig. 1).
MKP-1/ mice (C57BL/6 background) were obtained from Bristol-
Myers Squibb (via Professor Andy Clark, University of Birmingham,
UK) and crossed in-house with LDLR/ to produce the LDLR/
/MKP-1/ strain (Supplemental Fig. 2). The JNK1//LDLR/ andarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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litter sizes were reduced in the former compared to LDLR/ mice
(data not shown). All mice used in this study were female. Mice
were housed under speciﬁc-pathogen free conditions and studied
according to UK Home Ofﬁce regulations.
2.2. Composition of Western-type diet
Where indicated, normal chow diet was replaced at 10 weeks of
age with Diet W; a cholate-free high fat Western-type diet (Arie-
blok Diet W, 4021.06; Woerden, Netherlands) for 2e12 weeks. The
Diet W (High fat diet) consisted of (w/w) cocoa butter (15%),
cholesterol (0.25%), sucrose (40.5%), cornstarch (10%), corn oil (1%),
cellulose (5.95%), casein (20%), 50% choline chloride (2%), methio-
nine (0.2%) and mineral mixture (5.1%), total fat content (16%).
2.3. Lipoprotein, cholesterol and triglyceride analysis
Analysis for lipoprotein proﬁles and serum total cholesterol and
triglycerides was performed by fast protein liquid chromatography
using a size-exclusion column (Superose 6, PC 3.2/30, GE Health-
care, UK) and Inﬁnity™ Cholesterol (TR13421) or Triglycerides
(TR22421) Liquid Stable Reagents (Thermo Electron Corporation,
USA) as described [13].
2.4. Lesion analysis
En face lipid staining was carried out using Sudan IV as
described [15]. Brieﬂy, after termination by CO2 overdose, perfusion
ﬁxationwas carried out using 2% formalin (neutral buffer pH 7.0) at
37 C at a pressure of 110 cmwater for 5 min, via a cannula (Venoﬁx
23G; Medisave, UK) inserted in the left ventricle. Each aorta was
then stained using 5 ml Sudan IV (S4261-25; Sigma Aldrich, UK)
which was introduced into the left ventricle over a 5 min period.
The aorta was isolated and adventitial fat was removed. After cut-
ting along the outer curvature, the aorta was mounted and pho-
tographed (Olympus SZX16). En face plaque quantiﬁcation was
performed using ImagePro Plus software (version 5.1, Media Cy-
bernetics, Silver Spring, USA) by a single operator blinded to the
group allocation, and expressed as percentage of total aortic area
(lesion area fraction).
Cryosections of the aortic root were stained with Oil Red O and
Mayer's haematoxylin and lesions were analysed as we described
[13]. Brieﬂy, sectioning of the heart at the level of the aortic root
was carried out following themethod of Paigen and colleagues [16].
Five cryosections at 100 mm intervals were taken for each individual
heart, rinsed in water and then immersed in isopropanol for 30 s
before staining with Oil Red O (00625-25G; SigmaeAldrich) for
15 min followed by counterstaining using Harris' haematoxylin
(351945S; SigmaeAldrich). The sections were mounted and visu-
alized using an Olympus BX50 light microscope in identical light
conditions. The lesion area was quantiﬁed using ImagePro Plus
software by an experienced researcher who was blinded to the
experimental design. Mean lesion area values were obtaining by
averaging data from 5 aortic root sections. To correct for variation in
the alignment of sections, mean lesion area values were divided by
the mean area of the aortic wall and expressed as a percentage.
2.5. Immunostaining of aortic root cross sections
Cryosections of the aortic root were stainedwith antibodies that
recognise JNK1 (Cell Signalling Technology), CD68 (AbD Serotec;
macrophage marker), smooth muscle actin (Dako). After stringent
washing, sections were incubated with appropriate secondary an-
tibodies conjugated to biotin (Vector Laboratories) and with Avidinand Biotinylated horseradish peroxidase macromolecular Complex
prior to the application of VECTASTAIN substrate (Vector Labora-
tories). Alternatively, sections were stained using Gomori's tri-
chrome (Sigma) following the manufacturer's recommendations.
Sections were mounted and visualized by bright ﬁeld microscopy
(Nikon).
2.5.1. En face staining
Activation of caspase-3 in EC was measured by en face staining
of the murine aortic arch following [17]. Antibodies that recognise
active, cleaved caspase-3 were used (9661S; Cell Signalling Tech-
nology) [10]. Brieﬂy, aortae were perfusion ﬁxed and isolated prior
to permeabilisation using 0.5% Triton X-100 (SigmaeAldrich), and
blocking with 20% goat serum overnight at room temperature.
After washing with PBS, the tissue was incubated with anti-active
caspase-3 rabbit IgG antibodies overnight at 4 C. The tissue was
then washed with PBS and incubated with goat anti-rabbit IgG
antibodies conjugated to Alexa ﬂuor-568 (A11036; Invitrogen) for
2e3 h at room temperature followed by incubationwith anti-CD31
antibodies (directly conjugated to Alexa ﬂuor 488) for 72 h at 4 C.
After washing with PBS, the tissue was incubated with TOPRO-3 to
counterstain nuclei. To control for speciﬁc binding, tissues were
incubated with irrelevant rabbit IgG antibodies and appropriate
ﬂuorescent secondary antibodies, or were incubated with sec-
ondary antibodies alone. The ascending aorta and arch were
mounted and images of the EC monolayer were obtained using an
inverted laser-scanning confocal microscopy (LSM 510 Meta
inverted; Zeiss, Oberkochen, Germany). Protected (outer curva-
ture) and susceptible (inner curvature) regions of the aortic arch
were located using anatomical landmarks described by Iiyama and
colleagues [17]. The proportion of positive cells at each site was
quantiﬁed by analysis of multiple ﬁelds of view from athero-
susceptible or atheroprotected sites, and expressed as percentage
positivity.
En face TUNEL staining was carried out using an In situ Cell
Death Detection Kit (11684817910; Roche, Germany) as described
[10]. Aortae were ﬁxed and permeabilised before incubation with
TUNEL reaction mixture at 37 C for 1 h. After washing with PBS,
tissues were incubated with anti-FITC-biotin antibodies for 3 h at
room temperature and then with Streptavidin Alexa Fluor 488 for
2 h at room temperature. EC were co-stained using Griffonia lectin
conjugated to Rhodamine (Vector labs, USA) and nuclei were
counter-stained using TOPRO-3. Staining was assessed by laser-
scanning confocal miscroscopy (as above). EC were considered
apoptotic when TUNEL staining co-localized with pyknotic or
fragmented nuclei. To control for speciﬁc binding, tissues were
incubated with TUNEL reaction mixture that lacked labelled nu-
cleotides. The technique was validated by demonstrating that
DNAse treatment of portions of the murine aorta generated
enhanced TUNEL signals in EC (Supplemental Fig. 3).
2.5.2. Statistics
Differences between samples were analysed using an unpaired
or paired Student's t-test or one-way ANOVA with Bonferroni's
adjustment.
3. Results
En face staining revealed that exposure of LDLR/- mice to high
fat feeding for 2 or 6 weeks enhanced EC apoptosis at an athero-
susceptible site but not at a protected site, indicating that EC
apoptosis co-localises with early atherogenesis, suggesting a
contributing role (Supplemental Fig. 4). We examined the potential
role of JNK1 in EC injury and early lesion formation by studying
LDLR/ and LDLR//JNK1/mice exposed to a high fat diet for 6
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from caspase-3 activation and DNA fragmentation (Fig. 1A and B,
compare 1 and 5) and reduced lesion area in the aorta (Fig. 2A) and
aortic root (Fig. 2B), indicating that JNK1 contributes to EC
apoptosis and atherosclerosis. Analysis of macrophage, smooth
muscle cell and collagen content of aortic root lesions suggested
that deletion of JNK1 had little or no effect on plaque composition
(Supplementary Figs. 5, 6 and 7). It is unlikely that JNK1 promotes
atherogenesis by altering lipid metabolism since deletion of JNK1
did not inﬂuence cholesterol levels and had a modest effect on
plasma triglyceride levels (Fig. 2C and Supplemental Fig. 8).Fig. 1. JNK1 regulates endothelial injury in hypercholesterolemia. LDLR/, LDLR//JNK1/
activation was measured in EC by en face staining of susceptible (S) or protected (P) regions
stained using ToPro-3 (purple). (B) En face TUNEL staining was carried out at susceptible (S
lectin (red). Representative images (positive cells indicated by arrows) and quantitation of aWe tested the hypothesis that MKP-1 reduces apoptosis and
lesion formationat atheroprotected sitesbycomparingEC injuryand
lesion formation in LDLR//MKP-1/ compared to LDLR/ mice.
Deletion ofMKP-1 enhanced EC apoptosis at an atheroprotected site
(Fig.1A andB, compare2 and4), but this interventiondid notmodify
lesion formation (Fig. 2A and B), composition (Supplementary
Figs. 5, 6 and 7), or plasma lipid proﬁles (Fig. 2C and Supplemental
Fig. 3) in mice exposed to a high fat diet for 6 weeks. We also
determined the potential inﬂuence of MKP-1 deletion on a later
stage of atherosclerosis but observed that lesion sizes in the aorta
were similar in LDLR//MKP-1/ and LDLR/ mice exposed to aor LDLR//MKP-1/ mice were exposed to a high fat diet for 6 weeks. (A) Caspase-3
of the aorta (red; n ¼ 6 per group). Endothelial marker is CD31 (green) and nuclei were
) or protected (P) regions of the aorta (green; n ¼ 6 per group). Endothelial marker is
ctive caspase-3 and TUNEL-positive cells (mean ± SD) are shown. *p < 0.05, **p < 0.01.
Fig. 2. JNK1 promotes lesion formation. LDLR/, LDLR//JNK1/ or LDLR//MKP-1/mice were exposed to a high fat diet for 6 weeks. Aortic en face lesions (A) and aortic root
lesions (B) were quantiﬁed and expressed as a proportion of the entire aortic/aortic root area. (C) Total plasma cholesterol (left) or triglyceride (right) levels were measured and
mean values ± SD are shown. *p < 0.05, ***p < 0.001. It was observed that lesion area in the aorta (A) or aortic root (B) was signiﬁcantly higher in LDLR/ compared to LDLR/
/JNK1/ mice.
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reduced EC apoptosis during atherogenesis it did not protect
against early lesion formation.
4. Discussion
The JNK family of MAP kinases has been implicated in numerous
and diverse cellular activities and is known to be an important
regulator of vascular physiology [3e10]. However, the roles of
speciﬁc JNK isoforms have remained uncertain. Broad-spectrum
pharmacological inhibitors that target all three JNK isoform have
been shown to reduce atherosclerosis in mice [9]. On the other
hand, these inhibitors are likely to have deleterious side-effects
given the critical role of JNKs in physiological homoeostasis. In
this study, we demonstrate that genetic deletion the JNK1 gene can
reduce EC apoptosis and atherosclerosis in a murine model. Our
ﬁndings complement a previous study that demonstrated a role for
JNK2 in foam cell formation in hypercholesterolemic mice [9].
Taken together, these observations suggest that targeting of speciﬁc
JNK isoforms, JNK1 or JNK2, may have clinical utility for the pre-
vention of atherosclerosis whilst avoiding the potential adverse
effects of inhibiting all three JNKs.
The mechanism linking JNK1 activation with lesion formation is
likely to involve EC apoptosis which was reduced at atheroprone
sites by deletion of JNK1. The induction of EC apoptosis in LDLR/
animals required exposure to a high fat diet and occurred pre-
dominantly at a site of disturbed blood ﬂow, suggesting an inter-
action between hypercholesterolaemia, ﬂow and JNK1-dependent
EC injury. Although the levels of EC apoptosis detected were rela-
tively low (0.2e1%), it is plausible that they inﬂuence atheroscle-
rosis because low rates of apoptotic EC have previously been shown
to promote vascular disease [18,19] and have a major effect on the
permeability of the endothelial monolayer [20].
We demonstrated previously that JNK1 is activated in EC in
response to disturbed ﬂow in the murine aorta [12]. Moreover,
microarray analysis of cultured EC treated with a pharmacological
JNK inhibitor and subsequent siRNA-based analyses demonstrated
that JNK-c-Jun signalling primes EC apoptosis by inducing pro-
apoptotic transcripts [10]. Thus we propose that disturbed ﬂow
primes EC for apoptosis in response to hypercholesterolaemia by
promoting JNK1-dependent induction of apoptotic molecules. It is
important to note that other mechanisms may contribute to the
proatherogenic effects of JNK1 including effects on macrophages
and smooth muscle cell physiology [21e23]. Thus future studies
should be carried out using conditional knockouts to dissect out the
functions of JNK1 in EC and other cell types.
Our demonstration that MKP-1 deletion enhanced EC apoptosis
may be related to the ability of this molecule to suppress JNK1
activity at sites exposed to uniform ﬂow [12]. However, the
increased rates of apoptosis in response toMKP-1 deletionwere not
sufﬁcient to increase lesion formation which was similar in MKP-
1//LDLR/ and LDLR/- mice. These observations contrast with
previous reports where genetic deletion or pharmacological inhi-
bition of MKP-1 suppressed macrophage accumulation in arteries
and reduced lesion formation in ApoE/ mice [24e26]. These
apparent discrepancies may reﬂect differences in the murine
models used i.e. LDLR/- (current study) and ApoE/mice [24,25].
Compared to the ApoE/ model, LDLR/ mice develop relatively
mild hypercholesterolaemia and early lesions contain fewer mac-
rophages [15]. Thus the effects of MKP-1 onmacrophage inﬁltration
may dominate in ApoE/- mice but not in the LDLR/ model. In
addition, the divergence of EC apoptosis v plaque size in LDLR/
/MKP-1/ and LDLR//JNK1/ mice may indicate that other
shear regulated dual speciﬁcity phosphatases are important in
JNK1 regulation, for example dual speciﬁcity phosphatases 5, 8, and16 [27]. Regardless of the explanation, these ﬁndings suggest that
the inﬂuence of MKP-1 on atherogenesis may vary according to
plasma cholesterol levels and inﬂammatory load. Overall, our study
suggests that targeting of JNK may have clinical utility for the
prevention or treatment of early atherogenesis.
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